Coronel MRC

Idioma: Español
Referencias bibliográficas: 40
Paginas: 129-136
Archivo PDF: 93.31 Kb.

RESUMEN

La leucemia aguda linfoblástica (LAL) es el padecimiento maligno más frecuente de la población pediátrica. Las pruebas de laboratorio para el diagnóstico y pronóstico de la LAL en la infancia son indispensables para el clínico, sobre todo por el gran avance en el estudio de la biología de esta enfermedad. Estas pruebas permiten definir el riesgo y por ende dar un mejor tratamiento a los pacientes. Este padecimiento no es una entidad única sino una expresión muy amplia de la enfermedad; por esta razón los estudios de citomorfología, inmunofenotipos y citogenética y las técnicas de biología molecular pueden ofrecer un espectro extenso del estudio con alta sensibilidad. Por otro lado se puede lograr la detección temprana de enfermedad mínima residual que hasta el momento sigue siendo un gran reto en la hemato-oncología, para detectar las fallas de la terapéutica. El propósito de este trabajo es dar a conocer al clínico las pruebas necesarias para cada paciente con LAL así como la experiencia del Laboratorio de Hemato-oncología en este tipo de exámenes.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Ries LA, Kosary CL, Hankey BF, et al. SEER Cancer Statistics Review, 1973-1996. Bethesda, Md National Cancer Institute 1999. Last accessed December 17, 2004.

2. Smith MA, Ries LA, Gurney JG, et al. Leukemia. In: Ries LA, Smith MA, Gurney JG, et al. eds. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Bethesda, Md. National Cancer Institute, SEER Program, 1999. Last accessed November 03, 2004, pp 17-34. Last accessed April 14, 2004.

3. Xie Y, Davies SM, Xiang Y, et al. Trends in leukemia incidence and survival in the United States (1973-1998). Cancer 2003; 97(9): 2229-35.

4. Peris R. Registro Nacional de Tumores infantiles. Conselleria de Sanitat i Consum de la Generalitat Valenciana, 1994.

5. Rivera LR, Leal LC, Cárdenas CR. A survey of 4076 children with cancer. Certain epidemiological aspects from a single institution. Bol Med Hosp Infant Mex 1996;53(12):508-605.

6. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 1998; 339 (9): 605-15.

7. Pui CH. Acute lymphoblastic leukemia in children. Curr Opin Oncol 2000;12(1):3-12.

8. Woessner S, Lafuente R, Florensa L. Contribución de la histoquímica al diagnóstico hematológico. En: Woessner S. La Citología Óptica en el Diagnóstico Hematológico. Barcelona Medici, 1991;pp35-54.

9. Greaves M. Molecular genetics of ALL. Hematological 2000. EHAS Educational Book, 2000;p95.

10. Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukemia: current status and future perspectives. Lancet Oncol 2001;2:597-607.

11. Raimondi SC, Pui CH, Behm FG. Cytogenetically different leukemic clones at relapse of childhood acute lymphoblastic leukemia. Blood 1993;82:576-80.

12. Harris NL, Jaffe ES, Vardiman JW, Flandrin G. WHO classification of tumors of hematopoietic and lymphoid tissues. Lyon. IARC Press, 2001:12-3

13. Ross ME, Zhou X, Song G, Shurtleff SA, Downing JR. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 2003;102:2951-9.

14. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14 (1):18-24.

15. Trueworthy R, Shuster J, Look T, et al. Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood. Pediatric Oncology Group Study. J Clin Oncol 1992;10 (4):606-13

16. Reiter A, Schrappe M, Ludwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84 (9):3122-33.

17. Rubnitz JE, Link MP, Shuster JJ, et al. Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood. 1994;84 (2): 570-3.

18. Pui CH, Gaynon PS, Boyett JM, et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002;359(9321):1909-15.

19. Isoyama K, Eguchi M, Hibi S, et al. Risk-directed treatment of infant acute lymphoblastic leukaemia based on early assessment of MLL gene status: results of the Japan Infant Leukaemia Study (MLL96). Br J Haematol 2002;118(4):999-1010.

20. Bennett JM, Catovsky D, Daniel MT, et al. The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations. Br J Haematol 1981;47(4):553-61.

21. Mahmoud HH, Rivera GK, Hancock ML, et al. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med 1993;329(5):314-9.

22. Bürger B, Zimmermann M, Mann G, et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol 2003;21(2):184-8.

23. Aronson AG, Hayden SI, Relamed MR. Spinal fluid cytology during chemotherapy of leukemia of the central nervous system in children. Am J Pathol 1995;63:528-37.

24. Rivera LR, Martínez GG, Cárdenas CR. La utilidad de la citocentrífuga en la detección temprana de células malignas. Patología 1989;27:43-8.

25. Bene MC, Castoldi G, Orfao A, et al. Proposals for the immunological classification of acute leukemias. European Group for the immunological characterization of leukemias. Leukemia 1995;9:1783-6.

26. Sanchez J, Serrano J, Madero L, et al. Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukemia after allogeneic transplantation. Br J Haematol 2002;116:686-94.

27. Knapp W, Dörken B, Stein H, von dem Borne AEGR. En: Leucocyte typing. Vol IV. White cell differentiation antigens. New York. Oxford University Press 1989.

28. Reaman GH, Sposto R, Sensel MG, et al. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children’s Cancer Group. J Clin Oncol 1999;17(2):445-55.

29. Rivera LR, Cardenas CR, et al. B-Lineage acute lymphoblastic leukemia of childhood. An institutional experience. Arch Med Res 1997;28:233.

30. Pui CH. Childhood leukemias. N Engl J Med 1995;332(24): 1618-30.

31. Koehler M, Behm FG, Shuster J, et al. Transitional pre-B-cell acute lymphoblastic leukemia of childhood is associated with favorable prognostic clinical features and an excellent outcome: A Pediatric Oncology Group study. Leukemia 1993;7(12):2064-8.

32. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 1998;339(9):605-15.

33. Navid F, Mosijczuk AD, Head DR, et al. Acute lymphoblastic leukemia with the (8;14)(q24;q32) translocation and FAB L3 morphology associated with a B-precursor immunophenotype: the Pediatric Oncology Group experience. Leukemia 1999;13(1):135-41.

34. Behm FG, Head DR, Pui CH, et al. B-precursor ALL with unexpected expression of surface immunoglobulin (sig) mu and lambda. Lab Invest 1995;72:A-613,106a.

35. Uckun FM, Sensel MG, Sun L, et al. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood 1998;91(3):735-46.

36. Schneider NR, Carroll AJ, Shuster JJ, et al. New recurring cytogenetic abnormalities and association of blast cell karyotypes with prognosis in childhood T-cell acute lymphoblastic leukemia: a pediatric oncology group report of 343 cases. Blood 2000;96(7):2543-9.

37. Pui CH, Rubnitz JE, Hancock ML, et al. Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia. J Clin Oncol 1998;16(12):3768-73.

38. Baruchel A, Cayuela JM, Ballerini P, et al. The majority of myeloid-antigen-positive (My+) childhood B-cell precursor acute lymphoblastic leukaemias express TEL-AML1 fusion transcripts. Br J Haematol 1997;1:101-6.

39. Szczepanski T, Van Dongen JM. Minimal residual disease in leukemia patients. Lancet Oncol 2001;2:409-17.

40. Pine RS, Moy FH, Jayabose S. Real –time quantitative PCR: Standardized detection of minimal residual disease in pediatric acute lymphoblastic leukemia. J Pediatr Hematol/Oncol 2003;25:103-8.